The MICALs are a Family of F-actin Dismantling Oxidoreductases Conserved from Drosophila to Humans

Heng Wu1, Hunkar Gizem Yesilyurt1, Jimok Yoon1,2 & Jonathan R. Terman1

Cellular form and function — and thus normal development and physiology — are specified via proteins that control the organization and dynamic properties of the actin cytoskeleton. Using the Drosophila model, we have recently identified an unusual actin regulatory enzyme, Mical, which is directly activated by F-actin to selectively post-translationally oxidize and destabilize filaments — regulating numerous cellular behaviors. Mical proteins are also present in mammals, but their actin regulatory properties, including comparisons among different family members, remain poorly defined. We now find that each human MICAL family member, MICAL-1, MICAL-2, and MICAL-3, directly induces F-actin dismantling and controls F-actin-mediated cellular remodeling. Specifically, each human MICAL selectively associates with F-actin, which directly induces MICALs catalytic activity. We also find that each human MICAL uses an NADPH-dependent Redox activity to post-translationally oxidize actin’s methionine (M) M44/M47 residues, directly dismantling filaments and limiting new polymerization. Genetic experiments also demonstrate that each human MICAL drives F-actin disassembly in vivo, reshaping cells and their membranous extensions. Our results go on to reveal that MsrB/SelR reductase enzymes counteract each MICAL’s effect on F-actin in vitro and in vivo. Collectively, our results therefore define the MICALs as an important phylogenetically-conserved family of catalytically-acting F-actin disassembly factors.
Figure 1. Each human MICAL family member (MICAL-1, MICAL-2, and MICAL-3) is a flavoenzyme that consumes NADPH. (a) Although variable in length (depicted with the white dashed lines), each of the human (h) MICAL protein family members contains the same core domains as Drosophila (d) Mical including a flavoprotein monooxygenase (FM) domain (also called the redox or MO domain), a single calponin homology domain, and a single LIM domain. Multiple different splice forms of the MICALs have also been identified – some without the C terminus – as detailed in a recent review67. (b) Amino acid sequence alignments show that each of the human MICALs (M1, M2, M3), similar to Drosophila Mical (dM), contains three sequence motifs that define them as flavoprotein monooxygenases69,91,92. Each MICAL contains an exact match with each of the 11 residues of the ADP binding region of FAD binding proteins (GxGxxG motif91), where (+) indicates that MICALs match the consensus, (**) indicates that MICALs match the highly important conserved residues, and (.) indicates the conserved spacing of these residues within these motifs. The MICALs also have well-conserved FAD Fingerprint 2 (GD) and DG motifs, which are additional distinguishing features of flavoprotein monooxygenases69,92. Note, however, that MICAL-1 has a “naturally” occurring substitution of an alanine residue instead of the important aspartate residue in the DG motif. light blue = hydrophobic and cysteine residues, purple = acids, green = bases, yellow = proline, and orange = glycine. The proline (**) in the FAD fingerprint 2 is also likely to be conserved. (c–f) Each of the human MICALs binds FAD. The isoalloxazine ring system within flavins generates the yellow/orange color of FAD and FMN and is also responsible for light absorption in the UV and visible spectral range such that the oxidized form of FAD has two peaks at ~360 nm and ~450 nm93. Likewise, each of the purified human MICAL proteins, similar to Drosophila Mical76, has a UV-visible light absorption spectra with peaks at ~360 nm and ~450 nm (black lines) – and denaturation of
Mical is the sole Drosophila member of the MICAL family of proteins, which also includes three human MICAL protein family members coded for by three separate genes, MICAL-1, MICAL-2, and MICAL-3 (Fig. 1a,12,18). Each member of the MICAL family of proteins contains a similar protein organization, and includes a redox enzymatic domain, a calponin homology (CH) domain, a LIM domain, and a number of Src-homology 3 (SH3)-domain (Px PX P) binding motifs (Fig. 1a,12,18). At the C-terminus, MICAL family members also contain a region that interacts with the Plexin transmembrane receptor10,16,17, which is a receptor for one of the largest families of extracellular guidance cues, the Semaphorins12,18,19, which are involved in guidance of axon outgrowth20,21, synaptogenesis22,23, and muscle formation24,25, cardiovascular function26,27, cell division/cytokinesis28,29, exocytosis30,31, and cell viability32. Likewise, altered levels of MICAL expression and polymorphisms in MICAL have been linked to different neuronal and non-neuronal pathologies including cancer33,34,41–47, diabetic nephropathy30, blood brain barrier dysfunction29, muscular dystrophy34, liver disease35, infectious susceptibility46,47, epilepsy32, neurological disorders33–35, neurodegenerative disease36, aging37, skeletal anomalies38, and obesity48. Yet, Drosophila Mical remains the best-characterized MICAL family member, and the actin regulatory properties of three mammalian members of the MICAL family of proteins, including comparisons among the different family members, remain poorly defined.

Herein, we find that each of the human MICAL proteins is an F-actin disassembly enzyme. Our results reveal that human MICALs-1, 2, and 3 directly associate with actin filaments, which activate the MICALs to catalyze enzyme reactions that selectively oxidize actin. This MICAL-mediated oxidation of actin, dismantles filaments, inactivates actin-binding proteins, and allows actin to disassemble. Similarly, MICAL has been shown to also inactivate disease-associated actin-binding proteins such as cofilin16 and classical tyrosine phosphatase SHP250.

Our previous results revealed that the oxidoreductase (redox) region of Drosophila Mical (Fig. 1a) is sufficient to post-translationally oxidize and disassemble actin filaments11,13,14, but Mical's calponin homology (CH) domain (Fig. 1a) may also assist the redox region in its catalytic efficiency65. Therefore, so that we could compare and contrast the actin regulatory properties of each of the MICAL family members (and do it in the same species), we expressed and purified recombinant proteins containing the redox and CH domains of each of the three human MICALs, hMICAL-1 (redoxCH), hMICAL-2 (redoxCH), and hMICAL-3 (redoxCH) (Supplementary Figures 1–3). The redox regions of both invertebrate and vertebrate members of the MICAL family of proteins are highly conserved with as high as 63% identity between Drosophila and human family members (Supplementary Figure 4a). Likewise, primary sequence analysis of Drosophila and human family members revealed that each of them has within its redox enzymatic domain three well-conserved amino acid motifs that are found in proteins that bind and utilize the redox enzyme co-factor flavin adenine dinucleotide (FAD) (Fig. 1a). Experimental analysis also identified that purified human MICAL-1 (redoxCH), MICAL-2 (redoxCH), and MICAL-3 (redoxCH) proteins, like Drosophila Mical (redoxCH), are yellow in color, a distinguishing feature of flavin binding proteins (flavoproteins), and also exhibited an absorption spectra similar to flavoproteins (Fig. 1c–f, Supplementary Figures 1–3). Protein denaturation studies also supported these observations, and demonstrated that recombinant Drosophila Mical and all three human MICAL proteins bind the flavin FAD non-covalently in a 1:1 MICAL:FAD stoichiometry (Supplementary Figure 4b,c). Thus, each of the human MICALs, like Drosophila Mical, is an FAD binding protein.

Proteins that bind FAD typically perform oxidation-reduction reactions, so we wondered if all members of the MICAL family of proteins do the same. Primary sequence analyses revealed that MICAL family proteins are...
Figure 2. Each human MICAL family member directly binds and disassembles actin filaments. (a) Each of the purified human MICALredoxCH proteins, hMICAL-1 (hM-1), hMICAL-2 (hM-2), hMICAL-3 (hM-3), and hMICAL-1 DG (hM-1DG), like Drosophila MicalredoxCH (dM), associates with F-actin as revealed by actin co-sedimentation/pelleting assays in which Coomassie blue stained gels are shown. Notice that after high-speed centrifugation, each of the purified MICALs is present in the soluble (S) fraction (left gel). In the presence of purified actin filaments, however, each of the MICALs is present in the pellet (P) fraction (right gel). The percentage (± the standard error of the mean (SEM)) of different MICAL proteins in the pelleted fraction following incubation with purified F-actin was quantified by densitometry (n = 3). Bovine serum albumin (BSA) was used as a control and was predominantly found in the S fraction. [MICALs] = 600 nM, [BSA] = 600 nM, [actin] = 2.3 μM. (b,c) Each of the human MICALs alters actin polymerization and depolymerization. Pyrene-labeled actin was used to monitor both the polymerization and depolymerization of actin using standard approaches, where the fluorescence intensity (a.u. (arbitrary units)) of the pyrene-labeled actin polymer is substantially higher than the pyrene-labeled actin monomer. Each of the MICALs and the reaction conditions are color-coded here and in Figs 3,5. (b) Standard pyrene-actin polymerization assay. No filaments are present at Time = 0, when MICALs are added to actin and polymerization is induced. As can be observed by following the characteristic increase in fluorescence intensity over time, the addition of each of the purified human MICALs (in the presence of their co-enzyme NADPH) decreases the rate (r), extent (e), and...
steady-state level (ss) of actin polymerization (as compared to an actin only control, black dots; or MICAL only (no NADPH) + actin controls; or NADPH only + actin controls (not shown; see11)). Notably, MICAL (NADPH) induces actin polymerization to slow-down over time, which is followed by a substantial decrease in the extent of polymerization, the rapid depolymerization of F-actin, and the inability of actin to reinitiate polymer formation. Thus, because each of the MICALs acts on F-actin11,14 (and herein), our data in the polymerization assays are consistent with a model in which as the actin begins to polymerize, the MICALs oxidize individual subunits of the polymer, which disassembles the polymerizing actin. This slows polymerization – and also creates fewer and fewer unoxidized monomers that can be used for polymerization. [MICAL-1] = 300 nM, [dMical and MICALs-2, 3] = 600 nM, [NADPH] = 100 μM, [Actin] = 1.15 μM. (c) Purified human MICALs +/- NADPH was added to actin that was polymerized and kept in buffer conditions that favored polymerization (as can be seen with the steady-state fluorescence intensity level of the actin only control (black dots)); or actin with each of the MICALs without NADPH (not shown; see11)). The addition of each of the human MICALs (in the presence of NADPH) induces actin depolymerization (decreasing fluorescence intensity that can be followed over time in the pyrene actin depolymerization assay (left)). [MICAL-1] = 300 nM, [dMical and MICALs-2, 3] = 600 nM, [NADPH] = 100 μM, [Actin] = 1.15 μM. The extent of this MICAL (NADPH) dependent actin depolymerization is also observed when MICAL-treated F-actin was subjected to high-speed centrifugation to differentiate F-actin (P) from G-actin (S). As can be observed in these Coomassie stained gels, each of the human MICALs (in the presence of NADPH) substantially increases the ratio of G-actin to F-actin (arrowhead). [MICAL-1] = 300 nM, [dMical and MICALs-2, 3] = 600 nM, [NADPH] = 100 μM, [Actin] = 1.15 μM. Unprocessed original scans of gels are shown in Supplementary Fig. 11.

similar to a class of redox enzymes called flavoprotein monooxygenases12, and this similarity was also observed when the redox portion of mouse MICAL-1 was crystallized, examined structurally, and found to be most similar to the flavoprotein monooxygenase enzyme p-hydroxybenzoate hydroxylase (pHBH)63–65. Flavoprotein monooxy-
genases such as pHBH utilize the pyridine nucleotide coenzyme nicotinamide adenine dinucleotide phosphate (NADP) in their redox reactions63–65, so we compared the redox properties of each member of the human MICAL family. Our results revealed that each mammalian MICAL family member, like Drosophila Mical, consumes NADPH (Fig. 1g). Furthermore, we found that similar to Drosophila Mical, hMICAL-1, 2, and 3 are more active in the presence of NADPH than with the related pyridine nucleotide coenzyme NADH (Fig. 1h). However, we also noticed differences in the redox properties among the different MICAL family members. For example, hMICAL-redoxCH-1 is substantially more active than the other members of the MICAL family in the absence of a substrate and consumes high levels of NADPH on its own (Fig. 1g). In contrast, hMICAL-redoxCH-2, hMICAL-redoxCH-3, and Drosophila MICAL-redoxCH are most similar to each other with regards to NADPH consumption (Fig. 1g), and most similar to PhBH in that they each have relatively weak NADPH consumption activity on their own (i.e., in the absence of a substrate). Collectively, these results indicate that all members of MICAL family of proteins exhibit redox activity – although there are notable differences between family members in their catalytic properties.

Each Human MICAL Family Member Directly Binds and Dismantles Actin Filaments. Drosophila Mical directly binds and disassembles F-actin in an NADPH-dependent manner11,14, so we wondered if each of the human MICAL proteins also functions in a similar way. We first looked at the ability of hMICAL redoxCH-1, hMICAL redoxCH-2, and hMICAL redoxCH-3 proteins to associate with actin filaments using actin co-sedimentation assays. Like Drosophila Mical, co-sedimentation assays revealed that all three human MICALs physically associate with F-actin (Fig. 2a). Likewise, we found that these MICAL–F-actin interactions are specific, since similar to Drosophila Mical, human MICALs did not directly associate with microtubules (Supplementary Figure 5a). Thus, we wondered if human MICALs affect F-actin stability. Using different actin polymerization and depolymerization assays including pyrene-actin and sedimentation analyses, we found that each of the human MICALs, similar to Drosophila Mical11, altered actin polymerization and induced the disassembly of F-actin (Fig. 2b,c). Namely, when added prior to actin polymerization, each of the MICALs induces actin polymerization to slow-down over time, which is followed by a substantial decrease in the extent of polymerization, the rapid depolymerization of F-actin, and the inability of actin to reinitiate polymer formation (Fig. 2b11). In a similar way, when added to polymerized actin, each of the MICALs induces the disassembly of filaments (Fig. 2b11). Moreover, like Drosophila Mical11, these effects on polymerization and depolymerization were specific to F-actin, as microtubule polymerization and depolymerization dynamics were not affected by human MICALs (Supplementary Figure 5b). Further analysis revealed that each of the human MICALs effects on polymerization, like Drosophila Mical11, were more robust in the presence of NADPH versus NADH (Supplementary Figure 6a,b). These results therefore reveal that each of the human MICALs directly associates with actin filaments – inducing both F-actin disassembly and preventing normal F-actin reassembly.

Actin Filaments Serve as a Direct Substrate for Each MICAL Family Member. We next sought to examine the mechanism by which the human MICALs alter actin dynamics. Our previous results revealed that actin filaments exhibit the characteristics of a direct Mical substrate, robustly increasing the enzyme activity of Drosophila Mical (Fig. 3a11). Likewise, we found that the enzyme activity of each of the human MICALs, as judged by an increase in the consumption of the co-enzyme NADPH, increased in the presence of actin filaments (Fig. 3a). We also had previously determined that the methionine (Met) 44 and 47 residues of actin are the sites of Drosophila Mical post-translational oxidation of actin11, and that mutations to these residues makes actin resistant to Drosophila Mical11. Likewise, using an antibody that specifically recognizes the Mical-oxidized

---

**SCiENTifiC  REPORTS  |  (2018) 8:937  | DOI:10.1038/s41598-017-17943-5**
Figure 3. Each human MICAL family member is activated by actin filaments, oxidizing the Met44 residue of actin to induce F-actin disassembly. (a) The enzymatic activity of each of the human (h) MICALs, similar to Drosophila (d) Mical, notably increases in the presence of F-actin. Enzyme activity was determined by consumption (conversion of NADPH to NADP$^+$) of MICAL’s co-enzyme NADPH, which was monitored by recording the light absorbance at 340 nm wavelength/time. [MICALs] = 600 nM; [NADPH] = 200 μM. (b) Each of the human MICALs oxidizes the Met44 residue of actin, as determined using an antibody that specifically recognizes Mical-oxidized actin (actin$^{MetO44}$). Similar amounts of actin (lower panel) are present in all experiments. Note, as described in the methods, actin was polymerized to generate F-actin and 600 nM of each of the human MICALs and 200–300 μM of NADPH were added to 1.15 μM of F-actin at room temperature for 2 hours. (c) Each of the human MICALs requires actin’s Met44 and Met47 residues to disassemble F-actin. Drosophila Mical oxidizes the Met44 and Met47 residues of actin$^{13}$ and so we substituted as previously described a chemically related leucine residue for the methionine 44 and 47 residues in actin (M4447L)$^{13}$ to determine if each of the human MICALs also requires these residues to disassemble F-actin. Sedimentation assays reveal that each of the human MICALs robustly disassembles filaments composed of wild-type (WT) actin but not M4447L actin. [Actin] = 1.15μM; [MICALs-1, 1DG, 2, and 3] = 600 nM; [NADPH] = 200–300 μM.
(d) The stereospecific methionine sulfoxide reductase SelR/MsrB restores the polymerization properties of actin treated with each of the human MICALs. Pyrene-actin assays, where the fluorescence is higher in the polymerized state, revealed that SelR restores the polymerization of human MICAL-1 (hM-1), human MICAL-2 (hM-2), and human MICAL-3 (hM-3) treated actin. Buffer (buffer that SelR is stored in), n.u. (normalized units between the 2 graphs). [MICAL-1] = 100 nM, [dMical and MICALs-2, 3] = 600 nM, [NADPH] = 100μM, [Actin] = 1.15μM. Unprocessed original scans of gels/blots are shown in Supplementary Fig. 11.

Met44 residue of actin, we found that Met44 is oxidized by human MICALs 1, 2, and 3 (Fig. 3b) – and that mutating the Met44 and Met47 residues of actin prevents each of the human MICALs from disassembling F-actin (Fig. 3c). Moreover, we previously determined that the methionine sulfoxide reductase enzyme SelR/MsrB specifically reverses Drosophila Mical-mediated oxidation of actin through reduction of the oxidized Met44 and Met47 residues of actin – and that this SelR/MsrB-mediated effect also restores the polymerization properties of Mical-treated actin. Thus, we wondered if each member of the MICAL family also works in a similar way to oxidize actin and if SelR/MsrB could reverse this modification and restore the polymerization properties of human MICAL-treated actin. Indeed, we found that the methionine sulfoxide reductase enzyme SelR/MsrB restored the polymerization properties of actin that had been treated with each of the human MICALs (Fig. 3d). These results therefore reveal that actin serves as a direct substrate of mammalian MICALs and that the Met44 and 47 residues are essential for the ability of each of the human MICALs to disassemble F-actin. Likewise, since SelR/MsrB enzymes specifically catalyze the reduction of the R isomer of methionine sulfoxide (methionine-R-sulfoxide) to methionine (reviewed in [18,25]), these results also indicate that each MICAL family member oxidizes actin stereospecifically in the R-isomer to generate Met44,47-R-sulfoxide (actin).

**MICAL-1 exhibits notable differences in its activation and catalytic activity in comparison to other MICAL family members.** Our results herein reveal that each member of the MICAL family of proteins uses its enzyme activity to covalently modify and disassemble F-actin, but we also noticed that MICAL-1 exhibited pronounced differences in this catalytic activity when compared to other MICAL family members. In particular, in the absence of their F-actin substrate, Drosophila Mical and human MICALs 2 and 3 consumed relatively low amounts of their essential co-enzyme NADPH (Figs 1g, 3a, 4a) [13]. MICAL-1, in contrast, consumed much higher levels of oxygen in the absence of a substrate (Fig. 4a13). Thus, we wondered if each member of the MICAL family also works in a similar way to oxidize actin and if SelR/MsrB could reverse this modification and restore the polymerization properties of human MICAL-treated actin. Indeed, we found that the methionine sulfoxide reductase enzyme SelR/MsrB restored the polymerization properties of actin that had been treated with each of the human MICALs (Fig. 3d). These results therefore reveal that actin serves as a direct substrate of mammalian MICALs and that the Met44 and 47 residues are essential for the ability of each of the human MICALs to disassemble F-actin. Likewise, since SelR/MsrB enzymes specifically catalyze the reduction of the R isomer of methionine sulfoxide (methionine-R-sulfoxide) to methionine (reviewed in [18,25]), these results also indicate that each MICAL family member oxidizes actin stereospecifically in the R-isomer to generate Met44,47-R-sulfoxide (actin).

To further investigate these differences among the MICALs we wondered what effect this MICAL-1-mediated large increase in H$_2$O$_2$ production might have on F-actin dynamics. It has been suggested that the MICALs use H$_2$O$_2$ to exert their effects5,6,68. However, our previous results using multiple different approaches and those of others demonstrated that MICALs do not use the non-specific release of H$_2$O$_2$ or other diffusible oxidants to alter F-actin dynamics14,15,16,69, but need to be in close proximity to F-actin, which directly activates Mical to oxidize the Met44 and Met47 residues of actin14. Likewise, our results support these conclusions for each of the mammalian MICALs, since we observe an excessive difference in H$_2$O$_2$ production between human MICAL-1 and other MICAL family members (Fig. 4b, Supplementary Figure 7b). Further, our results reveal that MICAL-1 no longer disassembles F-actin when it is incubated with a F-actin substrate, such that it can no longer use NADPH in its reaction to modify actin. Drosophila Mical, in contrast, has a low rate of basal NADPH consumption (Figs 1g, 3a and 4a), retains NADPH levels in the absence of its F-actin substrate, and exhibited similar effects on F-actin disassembly in each condition (Fig. 4b).
MICAL-1 exhibits a single amino acid alteration that produces high levels of catalytic activity in the absence of its F-actin substrate. Since MICAL-1, unlike other MICAL family members (and MICAL-class enzymes like pHBH), has a high level of enzymatic activity in the absence of a substrate, we wondered what molecular variation(s) might be underlying this difference. Interestingly, comparing the sequences for the different MICALs revealed that the critical aspartate (D) amino acid residue in the DG motif of the flavin adenine dinucleotide (FAD) binding motif was instead an alanine (A) residue in MICAL-1 (Fig. 1b). The DG motif (also called the Conserved Motif⁶⁵) is critical for binding the pyrophosphate moiety of FAD (reviewed in⁶⁵), and so this “naturally-occurring” MICAL-1-specific substitution of a nonpolar alanine residue for the charged aspartate residue would be predicted to alter the positioning and flexibility of the FAD. This “naturally-occurring” MICAL-1-specific substitution might also enable MICAL-1 to be more catalytically active in the absence of its F-actin substrate than other MICALs. To test this hypothesis, we used site-directed mutagenesis to convert the alanine residue within the DG motif of MICAL-1 to an aspartate residue and thereby generated a MICAL-1 protein similar to the other MICAL family members (MICAL-1DG; Fig. 5a, Supplementary Figure 8). Our initial analysis of this MICAL-1DG protein revealed that it was similar to wild-type MICAL-1 (and other MICAL family members) – yellow in color (Supplementary Figure 8) and displaying the enzymatic features and absorption spectra of MICAL-class enzymes (Fig. 5b; Supplementary Figure 4b,c). Yet, strikingly, we also found that making this DG substitution decreased MICAL-1’s basal consumption of NADPH by close to 12-fold (1200%) per second (Fig. 5c) – enabling MICAL-1DG to consume much lower levels of oxygen and generate far less H₂O₂ than wild-type MICAL-1 (Fig. 4b,c). However, making this DG substitution did not decrease MICAL-1’s actin regulatory properties – since we observed that MICAL-1DG still bound actin filaments (Fig. 2a), was activated by F-actin (Fig. 5d), oxidized actin’s Met44 residue (Fig. 3b), and had robust and specific effects on both actin polymerization and depolymerization (Figs 2c, 5e; Supplementary Figure 5a,b). Furthermore, these MICAL-1DG effects on F-actin dynamics were dependent on the Met44 and Met47 residues of actin and could be counteracted by SeR (Figs 3c, 5f). Therefore, despite the large differences in H₂O₂ production between MICAL-1DG and wild-type MICAL-1, we did not observe any widespread differences in their actin regulatory abilities (Figs 2c, 5e). Indeed, our results revealed that MICAL-1DG became more efficient than MICAL-1 at altering actin dynamics (Supplementary Figure 9) – because it now had a lower basal level of NADPH consumption and generated less H₂O₂. Thus, these results further support that the MICALs do not use general H₂O₂ production to exert their effects on actin dynamics. Furthermore, these results also indicate that the aspartate (D) to alanine (A) substitution that occurs “naturally” in MICAL-1 underlies differences in basal activity and H₂O₂ production between MICAL-1 and the other MICAL family members.

Mammalian MICALs Regulate F-actin Disassembly and Cellular Remodeling In Vivo. Our biochemical experiments reveal that each member of the MICAL family of proteins functions to directly induce actin disassembly. We conducted these experiments using purified proteins in vitro so we wondered if each MICAL family member could also exert similar effects on F-actin organization in vivo. Bristle cells in the model organism Drosophila have long-provided a high-resolution single cell system for characterizing F-actin alterations in vivo (Fig. 6a,26-27) – and our previous results revealed that Drosophila Mical induces F-actin disassembly in a redox-dependent manner to remodel these cells¹¹,¹³,¹⁴. We therefore turned to this model system to determine if each member of the MICAL family has a similar ability – and tested this by generating transgenic flies expressing human MICALs corresponding to the exact protein construct we used in vitro, hMICAL-1redoxCH, hMICAL-2redoxCH, and hMICAL-3redoxCH. Notably, expressing each of the human MICALs in developing bristle cells using the bristle-specific driver (B11-GAL4) resulted in widespread and dramatic effects to actin organization and cellular morphology. The normally bundled and parallel-arranged F-actin (Fig. 6a, left and middle) that gives rise to a long slightly-curved bristle process (Fig. 6b, right) was significantly altered by expressing MICALs 1, 2 or 3 within them (Fig. 6b–e). Specifically, MICALs-1, 2, and 3 were each sufficient to decrease the presence of actin filaments in extending bristle processes (Fig. 6b–e, and compare to Fig. 6a) and resulted in substantial remodeling of bristle cells to generate numerous abnormal bends and branches (Fig. 6b–d). Furthermore, SeR, but not an enzyme dead version of SeR (SeRΔ⁵₄⁸), rescued the F-actin and morphological defects induced by MICALs-1, 2, and 3 (Fig. 6f), indicating that each of the human MICALs uses its redox activity to alter actin dynamics and cellular remodeling in vivo. Thus, as we observed in vitro using purified proteins, each of the human MICALs exerts specific negative effects on F-actin organization in vivo – effects that significantly remodel cells.

Discussion

Dynamic assembly and disassembly of the actin cytoskeleton allows cells to perform the functions necessary for normal development and physiology. Yet, while we have a considerable understanding of how actin filaments are assembled in cells, our understanding of how such filaments are disassembled remains highly incomplete¹⁰,²₂,²₃. Here, we provide an instrumental piece in the understanding of how filaments are disassembled, by characterizing a family of actin disassembly enzymes conserved from invertebrates to humans. In particular, members of the MICAL family of proteins, which includes one family member in invertebrates and three members in vertebrates including humans, are broadly expressed and have recently emerged due to their crucial role in directing
Figure 4. MICAL-1 exhibits notable activation and catalytic activity differences in comparison to other MICALs. (a) The enzyme activity of human MICAL-1 (hM-1) in the absence of its substrate F-actin is substantially higher than that of the other MICALs, as judged by consumption of NADPH. In particular, basal (in the absence of F-actin) NADPH consumption by MICAL-1 is close to 100 times more NADPH consumption per second than hMICAL-2, 60 times more NADPH consumption per second than Drosophila Mical, and over 10 times more NADPH consumption per second than hMICAL-3. \([\text{MICALs}] = 600 \text{nM}, [\text{NADPH}] = 200 \mu\text{M}\). (b) hM-1 generates substantially more hydrogen peroxide (H\(_2\)O\(_2\)) than other MICALs (all assays done in the presence of NADPH and the absence of F-actin). Upper panel, chemiluminescent detection of H\(_2\)O\(_2\) produced by MICALs, reveals significant H\(_2\)O\(_2\) production by hM-1 in comparison to others MICALs that is quantified using a different assay, a bioluminescent assay (lower panel). Also note in both panels that hM-1DG generates substantially less H\(_2\)O\(_2\) than hM-1. \([\text{MICALs}] = 600 \text{nM}; [\text{NADPH}] = 100 \mu\text{M}\). (c) hM-1 consumes substantially more oxygen (O\(_2\)) than other MICALs (all assays done in the presence of NADPH and the absence of F-actin). Also note that hM-1\(^{1DG}\) consumes substantially less O\(_2\) than hM-1. \([\text{MICALs}] = 600 \text{nM}; [\text{NADPH}] = 200 \mu\text{M}\). (d,e) Pyrene-actin assays reveal that hMICAL-1 (d), unlike hMICAL-2 (Supplementary Figure 7d), hMICAL-3 (e) and Drosophila Mical\(^{11}\), exhibits decreasing effects on F-actin when higher levels of it are added to F-actin. These effects are consistent with hMICAL-1 exhibiting such rapid consumption of NADPH in the absence of its F-actin substrate that NADPH becomes limiting in allowing MICAL-1 to alter F-actin dynamics (see also main text). \([\text{Actin}] = 1.15 \mu\text{M}, [\text{NADPH}] = 100 \mu\text{M}\). (f–h) hMICAL-1 generates a high-level of basal H\(_2\)O\(_2\), but does not use H\(_2\)O\(_2\) to modify actin dynamics. (f) To test if MICALs use H\(_2\)O\(_2\) to disassemble F-actin we made use of MICAL-1’s high level of basal activity to produce H\(_2\)O\(_2\) in the presence of NADPH, and added NADPH either before (pre) or after (post) the
addition of F-actin. In short, we reasoned that if \( \text{H}_2\text{O}_2 \) (or another stable oxidant) was being used by MICALs to modify actin, it would not matter in which order we added F-actin to the same tube. However, if \( \text{H}_2\text{O}_2 \) (or another stable oxidant) was not being used to modify F-actin, MICAL-1 would exhaust its supply of NADPH generating \( \text{H}_2\text{O}_2 \) prior to the addition of F-actin, and would therefore have decreased effects on F-actin dynamics. (g) MICAL-1 no longer disassembles F-actin when it is incubated with NADPH prior to the addition of F-actin (pink), revealing it does not use \( \text{H}_2\text{O}_2 \) or another stable/generally-released oxidant to disassemble F-actin. (h) As a control, Drosophila Mical, which has a low rate of basal NADPH consumption (and thus retains NADPH when its F-actin substrate is not present), exhibits similar disassembly of F-actin in both the Pre- and Post- incubation conditions. [Actin] = 1.15 \( \mu \)M, [dMical and MICAL-1] = 600 nM, [NADPH] = 100 \( \mu \)M. Unprocessed original scans of blots are shown in Supplementary Fig. 11.

Our results also identifi
c unique biochemical attributes that define the MICAL family of enzymes. In particular, we find that each MICAL family member binds FAD, is enzymatically active, and behaves catalytically in a generally similar manner – including using NADPH as a co-enzyme, which the MICALs prefer over the related (unphosphorylated) pyridine nucleotide co-enzyme NADH. Likewise, we find that actin filaments activate the catalytic activity of each member of the MICAL family of proteins and serve as a substrate for each MICAL. Furthermore, we find that each of the MICALs uses the same mechanism to accomplish its dismantling effects on actin filaments: the stereospecific oxidation of specific methionine residues within the D-loop portion of actin subunits – effects that are reversed by SlerR/MsrB family methionine sulfoxide reductases. Thus, each MICAL family member is selective in its effects – such that it has a specific protein substrate that activates it, particular amino acid residues that it specifically modifies within that substrate, and a stereospecificity in how it modifies its amino acid substrate residues. These attributes, therefore, distinguish MICAL family enzymes from other physiologically-relevant redox enzymes characterized to date such as NADPH oxidases and nitric oxide synthases, which have different mechanisms of activation and action, as well as broader specificity both with regards to protein substrates and the amino acids that are modified within those substrates.

Our results also elucidate that a characteristic feature of each of the MICALs is that actin is their oxygen-acceptor substrate – and that specific binding of the polymeric form of this substrate (i.e., actin filaments) triggers MICALs consumption of NADPH to oxidize individual actin subunits. Thus, from both a structural perspective\(^{13,63-65} \) and in the way that binding of the oxygen-acceptor substrate accelerates consumption of the NADPH co-enzyme, MICALs are most similar to flavoprotein monoxygenase enzymes. However, to the best of our knowledge MICAL enzymes are the first known class of flavoprotein monoxygenases for which a protein substrate has been identified. Our results therefore raise the possibility that other (or perhaps all) flavoprotein monoxygenases have protein substrates that are awaiting identification. Moreover, it is unknown if the MICALs have other substrates, but our results herein reveal that a substrate for the MICALs should be defined based solely on its ability to both 1) activate MICAL and 2) be modified by MICALs enzymatic activity (i.e., as we have found for actin filaments). Such a definition will thus serve to differentiate a bona fide substrate from a protein that is simply spuriously modified by the ability of MICALs and other flavoprotein monoxygenases to produce non-selective diffusible oxidants (i.e., hydrogen peroxide) in the course of their reaction in vitro.

Our results also reveal that like other monoxygenases, the production of hydrogen peroxide (i.e., the loss of reducing equivalents in the absence of a substrate) is actively suppressed by MICAL family enzymes. However, there is some production of hydrogen peroxide, particularly in the case of MICAL-1, with its naturally-occurring single amino acid substitution that we have defined in the critical DG conserved motif of the MICAL enzymatic region. Thus, while our results herein, coupled with previous observations\(^{11,13,14,37} \) demonstrate that hydrogen peroxide production and MICAL-mediated F-actin disassembly are not linked together (see also Supplementary Figure 10), it is interesting to consider that MICAL may use hydrogen peroxide in physiological contexts to exert effects on other proteins. In any case, the effects that the MICALs may have using hydrogen peroxide are likely to be on cysteine residues, since hydrogen peroxide is a poor oxidizer of methionine residues\(^{24-25} \). Indeed, the oxidation of cysteine residues via hydrogen peroxide has been reported as a means through which MICAL-1 modifies the CRMP protein\(^{26} \). It should also be considered that in contrast to our work herein using truncated/active forms of MICAL, full-length MICALs (including MICAL-1) are kept in an inactive state (i.e., without NADPH activity/hydrogen peroxide production)\(^{11,13,28,37,62} \). Thus, any hydrogen peroxide production by MICALs is likely to be tightly controlled in the cell to modify proteins in the vicinity of F-actin. Future work will aim to further elucidate the mechanistic details of these unusual and important enzymes, including the means by which the MICALs gain access to and oxidize Met44 and Met47 within filaments (Supplementary Figure 10).
In summary, we have identified a family of actin regulatory proteins conserved from invertebrates to humans that use actin filaments as their enzymatic substrate—employing their unusual catalytic mechanism to cova-
lently modify and induce the dismantling of actin filaments. These findings therefore uncover a new class of 
broadly-expressed negative regulators of actin stability and thereby elucidate new mechanisms underlying actin 
disassembly. In particular, the assembly of actin filaments is favored within cellular contexts, making it critical 
to understand how targeted and rapid F-actin disassembly is occurring.

Figure 5. MICAL-1 exhibits a single amino acid alteration in its DG motif that produces high levels of catalytic activity in the absence of its F-actin substrate. (a) MICAL-1 has a “naturally” occurring substitution of an alanine (A) residue instead of the important aspartate (D) residue in the DG (Conserved) motif that is present in the other MICAL family members. Using site-directed mutagenesis we converted the alanine residue within the DG motif of MICAL-1 to an aspartate residue and thereby generated a MICAL-1 protein similar to the other MICAL family members (MICAL-1DG). (b) Purified MICAL-1DG protein still exhibits the hallmarks of an FAD-binding protein. In particular, MICAL-1DG maintains its UV-visible light absorption spectra (with peaks at ~360 nm and ~450 nm, black lines), and denaturation of the MICAL-1DG releases FAD, which underlies this absorption spectra (green line). [MICAL-1DG] = 20 μM. (c) Converting the alanine residue within the DG motif of MICAL-1 to an aspartate residue (MICAL-1DG), substantially reduces (12-fold per second) the basal (in the absence of its F-actin substrate) enzyme activity of MICAL-1, as judged by the consumption of NADPH. [MICALs] = 600 nM, [NADPH] = 200 μM. (d) The enzymatic activity of MICAL-1DG, similar to other MICALs, is notably increased in the presence of F-actin. Enzyme activity was determined by the consumption (conversion of NADPH to NADP+) of MICAL’s co-enzyme NADPH, which was monitored by recording the light absorbance at 340 nm wavelength/time. [MICAL-1DG] = 600 nM, [NADPH] = 200 μM. (e) MICAL-1DG, similar to unaltered MICAL-1 and other MICAL family members, induces actin polymerization to slow-down over time, which is followed by a substantial decrease in the extent of polymerization, the rapid depolymerization of F-actin, and the inability of actin to reinitiate polymer formation. [Actin] = 1.15 μM, [MICAL-1DG] = 600 nM, [NADPH] = 100 μM. Here, as in Fig. 2b, pyrene-labeled actin was used to monitor both the polymerization and depolymerization of actin using standard approaches, where the fluorescence intensity (a.u. (arbitrary units)) of the pyrene-labeled actin polymer is substantially higher than the pyrene-labeled actin monomer. (f) Similar to unaltered MICAL-1 and other MICAL family members, the stereospecific methionine sulfoxide reductase SelR/MsrB restores the polymerization properties of actin treated with MICAL-1DG. See also Fig. 3d. Buffer (buffer that SelR is stored in), n.u. (normalized units between the 2 graphs). [Actin] = 1.15 μM, [MICAL-1DG] = 600 nM, [NADPH] = 100 μM.

In summary, we have identified a family of actin regulatory proteins conserved from invertebrates to humans 
that use actin filaments as their enzymatic substrate—employing their unusual catalytic mechanism to cova-
lently modify and induce the dismantling of actin filaments. These findings therefore uncover a new class of 
broadly-expressed negative regulators of actin stability and thereby elucidate new mechanisms underlying actin 
disassembly. In particular, the assembly of actin filaments is favored within cellular contexts, making it critical 
to understand how targeted and rapid F-actin disassembly is occurring. In a similar way, specific cell-cell
Figure 6. Each human MICAL family member generates F-actin disassembly and cellular remodeling in vivo.
(a) Drosophila bristle cells serve as a model for examining actin organization and cellular morphology in vivo. Bristle cells are single cells composed of a cell body (cb) and a long F-actin-rich (green) cellular extension (arrowheads). The F-actin organization (green) in the bristle process can be easily observed throughout pupal development (left and the boxed region is shown at higher magnification in the middle), while the morphology of the single bristle cell can be observed both during development (left) and in adulthood (right). (b) Expression of hMICAL-1redoxCH specifically in bristles generates alterations in F-actin organization and cellular morphology. Notice the dramatic alterations to the height, width, and shape of the bristles (arrowheads) including branches (arrows) that can be seen in developing pupae (left) and in the image and drawings of single bristles from adults (right). Notice also that a similar degree of F-actin (green) is present in patches around the periphery of the cell body (cb), but that the extent of F-actin (green) in the bristle process (arrowheads) in much less compared to the wild-type control in (a) – such that there is an absence of actin filaments and it is more difficult to discern F-actin/F-actin bundles. Also, note that the F-actin is no longer arrayed in linear projecting bundles (as in a), but in small filaments and bundles of filaments with no apparent organization (left and in the boxed region shown at higher magnification). (c-d) Similar dramatic alterations in F-actin organization and bristle morphology as observed with hMICAL-1redoxCH (b) were also seen when hMICAL-2redoxCH (c) and hMICAL-3redoxCH (d) were specifically expressed in bristles. (e) Quantification of F-actin alterations following bristle expression of different human MICALs, as judged by animals that had a loss of parallel-arranged F-actin bundles. n = > 10 animals/genotype. (f) Quantification of F-actin/morphological defects present following bristle expression of different human MICALs, or in combination with SelR or a reductase-dead form of SelR (SelRC124S)14. Note that SelR significantly rescues the F-actin/morphological alterations induced by each of the human MICALs, while SelRC124S does not rescue these defects (and enhances the defects induced by hMICAL-2redoxCH and hMICAL-3redoxCH). hM-1 (hMICAL-1redoxCH), hM-2 (hMICAL-2redoxCH), hM-3 (hMICAL-3redoxCH). Chi-Square Test; ***P < 0.0001; n = > 10 animals/genotype.
signaling ligands including repellents such as ephrins, slits, semaphorins, myelin-associated inhibitors, and Wnts trigger the rapid disassembly of F-actin networks in multiple tissues \cite{20,25}, but their direct effectors are still poorly understood. Our results shed light on both of these phenomena, since MICALs are heavily alternatively spliced - with different forms being targeted to specific regions of cells and organelles, as well as working both together and independently from specific repellent cues (reviewed in \cite{18,22-23}). Indeed, a model is emerging that the MICALs are maintained in an inactive conformation in the cell and are locally activated upon binding to other proteins such as the Semaphorin repellent receptor Plexin and small GTPases like Rab35 (Supplementary Figure 1 \footnote{1,12,19,28,37,62}). Moreover, because of the MICALs ability to covalently modify actin, the MICALs differentiate themselves from other actin disassembly proteins characterized to date because they not only rapidly dismantle F-actin, but they also generate post-translationally modified actin that has aberrant assembly properties. Given that the MICALs are widely expressed in multiple different tissues, that they have the ability to synergize with ubiquitous actin regulatory proteins and signaling pathways, and that they (and their substrate residues on actin) have been tied to different pathologies, our results bring a new understanding to how targeted and rapid F-actin disassembly occurs in cells.

Materials and Methods

Molecular Biology and Protein Purification. For all protein expression, plasmids were transformed into ArcticExpress bacterial competent cells (Stratagene, La Jolla, CA, USA) using general approaches \cite{26}. For a given plasmid, a single clone was then inoculated into a 150 ml TB culture medium (including 100 \mu M ampicillin, 2 mM MgSO4, and 20 \mu M gentamicin) and shaken at 37 °C overnight. 25 ml of overnight culture was then transferred to six 2.8 L flasks containing 1 L TB media (with 100 \mu M ampicillin and 2 ml of AntiFoam B emulsion [Sigma, A6707-500ml]). Flasks were then cultured at 30 °C for ~8 hrs with shaking at 215 rpm. After ~8 hrs, the temperature of the shaking incubator was switched to 10 °C and isopropyl-\beta-D-thiogalactoside (IPTG) was added to each of the cultures to a final concentration of 0.5 mM, and each of the cultures were then shaken for 24 hrs. The bacteria was then collected by centrifugation at 2623 \times g for 30 min and bacterial pellets were fast frozen in liquid nitrogen and stored at −80 °C until use. The frozen bacterial pellets were thawed at RT and 100 ml of Lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 3 mM \beta-mercaptoethanol, 20 mM imidazole, 1 tablet of Roche Complete \textsuperscript{®} EDTA-free Protease Inhibitors Cocktail) was added to the combined pellets for a given construct and stirred until the pellet was completely dissolved. The dissolved sample was then loaded into a high-pressure homogenizer (EmulsiFlex-C5, Avestin, Inc., Ottawa, Ontario, Canada) pre-cooled for 1 hr using a refrigerated circulating bath set at 4 °C, and the bacteria were broken by increasing the pressure to 40 psi. In all cases, the output pressure was within 5,000–10,000 psi and the temperature of the sample was controlled by either immersion of the machine/tubing in ice or cooling and applying water using a re-circulating water bath. Initially, the cells were swirled during lysis to prevent cells from getting stuck in the machine and the lysis step was repeated two to three times (up to five times). As an alternative, the bacteria were lysed using a Misonix Ultrasonic Liquid Processor or similar and sonicated for 15 min at 50 amplitude, 5 s on and 5 s off. The bacterial sample in lysis buffer was then centrifuged at 22,000 \times g for 2 hrs. The supernatant was transferred to a new tube and centrifuged for another 30 min at the same speed. The supernatant was then filtered with a 0.45 \mu m filter.

To construct human (h) MICAL-1\textsuperscript{-redoxCH}, a portion of the human MICAL-1 cDNA coding for the redox and CH domains was PCR amplified using primers containing a 5’ Sall restriction enzyme site (Forward: 5’-AGCTGTGCGAGGTTACCTCAAGCTGCTCTACCTACCTCAG-3’) and a 3’ Xhol restriction enzyme site (Reverse: 5’-AGCTCTCTAGCTGATCAAGGCTGGTGGTGG-3’) and after digestion of the appropriately sized PCR product with Sall and Xhol, the fragment was inserted into the Sall and Xhol sites of the previously generated pET43.1bNG vector \cite{77}. Positive clones were confirmed by digestion with Sall/Xho and DNA sequencing. Following bacterial inoculation and preparation of the protein sample from bacteria as described above, the hMICAL-1\textsuperscript{-redoxCH} protein was purified (see also Supplementary Figure 1). In particular, a 5 ml HisTrapFF1-GE affinity column was equilibrated with Buffer Ni-A (10 mM Tris-HCl, pH8.0, 500 mM NaCl, 5% glycerol, 3 mM \beta-mercaptoethanol, 20 mM imidazole) and then the sample containing the hMICAL-1\textsuperscript{-redoxCH} protein was loaded onto the column. After washing the column with >20 column volumes (CV) of Buffer Ni-A, the sample was eluted from the column using elution buffer Ni-B (10 mM Tris-HCl, pH8.0, 500 mM NaCl, 5% glycerol, 3 mM \beta-mercaptoethanol, 250 mM imidazole) and collected in 1 ml aliquots. The presence of the MICAL-1\textsuperscript{-redoxCH} protein was then examined by SDS-PAGE and tubes enriched with the hMICAL-1\textsuperscript{-redoxCH} protein were retained and combined. The pooled protein sample was then prepared for thrombin digestion to remove the Nus solubility tag by first desalting and exchanging the buffer using a HiPrep 26/10 column (GE Healthcare Bio-Sciences Corporation, Piscataway, NJ, USA). After desalting and eluting with Desalting buffer (10 mM Tris–HCl, pH8.0, 50 mM NaCl, 5% glycerol, 1 mM DTT), the eluate was incubated with 100 \mu l of 10 \mu g/ml of the thrombin protease overnight in the cold room. After thrombin digestion, a 1 ml HisTrapFF1-GE affinity column was used to remove the Nus tag using Buffer Ni-A and elution Buffer Ni-B as described above. After another desalting step in which the sample was desalted and eluted using Buffer S-A (20 mM NaPO\textsubscript{4}, pH7.5, 10 mM NaCl, 5% glycerol, 1 mM DTT), the samples containing the MICAL-1\textsuperscript{-redoxCH} protein were loaded into a MonoS column (U96 S6 column [Bio-Rad] or Mono S 5/50 GL Column [GE Healthcare]), washed with Buffer S-A (20 mM NaPO\textsubscript{4}, pH7.5, 10 mM NaCl, 5% glycerol, 1 mM DTT) and eluted in 1 ml aliquots with Buffer S-B (20 mM NaPO\textsubscript{4}, pH7.5, 1 M NaCl, 5% glycerol, 1 mM DTT). 10 \mu l from each aliquot/collection tube was then electrophoresed on an SDS-PAGE gel and those corresponding tubes containing hMICAL-1\textsuperscript{-redoxCH} protein were combined together. Millipore Amicon Ultra centrifugal filter (Ultracel-50 kDa cutoff) was then used to reduce the volume to around 500 \mu l and to change the buffer to storage buffer (10 mM Tris pH8.0, 100 mM NaCl, 5% glycerol, 1 mM DTT). The protein sample was then aliquoted and fast frozen with liquid nitrogen and stored in a −80 °C freezer.

To construct human MICAL-2\textsuperscript{-redoxCH}, a portion of the human MICAL-2 cDNA encoding for the redox and CH domains was PCR amplified using primers containing a 5’ Sall restriction enzyme site
(Forward: 5′-AGCTGTCCGACGGTGCACTCTATCAGATGGGCGGAAACGAGGATGAGA-3′) and a 3′ AvrII restriction enzyme site (Reverse: 5′-AGCTTCAGTTAGTGTTGGTGGCTGCTCAGTACGGAGGAGGATGAGA-3′) and after digestion of the appropriately sized PCR product with Sall and AvrII, the fragment was inserted into the Sall and AvrII sites of the previously generated pET43.1bNG vector as described above. Positive clones were confirmed by digestion with Sall/AvrII and DNA sequencing. Following bacterial inoculation and preparation of the protein sample from bacteria as described above, hMICAL-1redoxCH protein was purified (see also Supplementary Figure 2). In particular, transformation, induction, pelleting, lysis, Ni2+-NTA affinity chromatography, desalting, and thrombin digestion were carried out as described for purification of hMICAL-1redoxCH. The protein sample was then loaded a second time onto a 5 ml HisTrapFF1-GE affinity column and washed with Buffer Ni-A and eluted with Buffer Ni-B. The protein sample was then desalted as described for hMICAL-1redoxCH and eluted with Buffer S-A, loaded onto a MonoS column, washed with Buffer S-A, and eluted with Buffer S-B. Collecting samples was then processed as described for hMICAL-1redoxCH and stored in a −80 °C freezer.

To construct human MICAL-3redoxCH, a portion of the human MICAL-3 cDNA encoding for the redox and CH domains was PCR amplified using primers containing a 5′ Sall restriction enzyme site (Forward: 5′-AGCTGTCCGACGGTGCACTCTATCAGATGGGCGGAAACGAGGATGAGA-3′) and a 3′ XhoI restriction enzyme site (Reverse: 5′-AGCTTCAGTTAGTGTTGGTGGCTGCTCAGTACGGAGGAGGATGAGA-3′) and after digestion of the appropriately sized PCR product with Sall and Xhol, the fragment was inserted into the Sall and Xhol sites of the previously generated pET43.1bNG vector as described above. Positive clones were confirmed by digestion with Sall/Xhol and DNA sequencing. Following bacterial inoculation and preparation of the protein sample from bacteria as described above, hMICAL-3redoxCH protein was purified (see also Supplementary Figure 3). In particular, to purify hMICAL-3redoxCH protein, Ni2+-NTA affinity chromatography was performed on a 5 ml HisTrapFF1-GE affinity column with Buffer Ni-A and Buffer Ni-B. The samples containing hMICAL-3redoxCH protein was then desalted as described above using Desalting Buffer, loaded onto a MonoQ column (Mono Q 5/50GL, GE Healthcare), washed with Buffer Q-A (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 5% glycerol, 1 mM DTT), and eluted with Buffer Q-B (10 mM Tris-HCl, pH 8.0, 1 M NaCl, 5% glycerol, 1 mM DTT). As described above for hMICAL-2redoxCH protein, the sample was then subjected to thrombin digestion, loading onto a 5 ml HisTrapFF1-GE affinity column, and desalting and purification using a MonoS column. Collected samples were then processed as described for hMICAL-1redoxCH and hMICAL-2redoxCH and stored in a −80 °C freezer.

To construct the human MICAL-1redoxCH D for A substitution (hMICAL-1DG), a portion of human MICAL-1redoxCH was PCR amplified using primers containing a 5′ Sall restriction enzyme site (Forward: 5′-AGCTGTCCGACGGTGCACTCTATCAGATGGGCGGAAACGAGGATGAGA-3′) and a 3′ AatII restriction enzyme site (Reverse: 5′-TGAATTTGACGTCCTTATCTCGGCTGATGGAGGTAAATTCGTCCCTGAAGGCTTC-3′) and into the TopoTA vector (Invitrogen) using the manufacturers recommended protocol. The resulting vector/insert was then cut with the restriction enzymes AatII and Spel. Then, another portion of human MICAL-1redoxCH was PCR amplified using a 5′ primer containing an AatII restriction enzyme site and a mutation of the AG residue of the DG motif to a DG residue (Forward Primer: 5′-TGAATTTGACGTCCTTATCTCGGCTGATGGAGGTAAATTCGTCCCTGAAGGCTTC-3′) and a 3′ primer containing both Xhol and Spe I restriction enzyme sites (Reverse Primer: 5′-AGCCTAAGTTCTGCTGACTTACCTGAGCTACTGTACCCGCTTC-3′). The resulting PCR product was then digested with AatII and Spel and inserted into the corresponding digested sites in the previously generated TOPO vector/insert. This newly generated MICAL-1redoxCH DG cDNA was then cut out of the TOPO vector and inserted into the Sall and Xhol sites of the previously generated pET43.1bNG vector as described above. Positive clones were confirmed by digestion with Sall/Xhol and DNA sequencing. Following bacterial inoculation and preparation of the protein sample from bacteria as described above, MICAL-1redoxCH DG protein was purified (see also Supplementary Figure 8). In particular, to purify MICAL-1redoxCH DG protein, identical approaches were followed to that described for hMICAL-1redoxCH protein, except an anion exchange chromatography was used for the final purification step including a MonoQ column (Mono Q 5/50GL, GE Healthcare), Q-A buffer, and Q-B buffer to elute the sample. Collected samples were then processed as described for hMICAL-1redoxCH, hMICAL-2redoxCH, and hMICAL-3redoxCH and stored in a −80 °C freezer.

UV-visible Spectroscopy and Related Analyses. Either a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA) or fluorescence spectrophotometer (Spectra Max M2; Molecular Devices, Sunnyvale, CA, USA) was used for all assays and scanning wavelengths between 250 nm and 700 nm were used. To determine whether the flavin was bound covalently or non-covalently and whether FMN or FAD was bound, 100 μl of purified MICAL proteins was used to obtain an absorbance spectrum with a NanoDrop spectrophotometer. 100 μl of purified MICAL proteins was used to obtain a fluorescence spectrum using a fluorescence spectrophotometer. 200 μl of 10 mM HEPES/NaOH, 50 mM NaCl buffer, pH 7.5 was added into each tube to dilute samples. The 5 tubes with samples were incubated for 10 min at 100 °C. After being cooled on ice, microfuge tubes are centrifuged at 4 °C for 10 min at 13,000 rpm (14,500 g). The supernatant was recovered and the absorbance spectrum was then recorded. The original data were then exported into Excel software (Microsoft Corp., Redmond, WA, USA) and presented using GraphPad software (La Jolla, CA, USA), to compare the difference between purified and denatured proteins. Calculation of the percentage of FAD bound to purified MICAL proteins (i.e., the stoichiometry of FAD to MICAL proteins) was done using standard approaches 76,79,80 such that the concentration of each of the purified MICALredoxCH proteins was determined as described above by adding 2 μl to the platform of a NanoDrop spectrophotometer and measuring the absorption at 280 nm. The concentration of FAD in the purified sample was then determined using standard approaches 76,79, by denaturing the MICALredoxCH proteins with 0.2% SDS, pelleting
the denatured MICAL\textsuperscript{redoxCH} proteins, measuring the absorbance of the free FAD in the sample, and then using the Beer-Lambert law (Absorption at 459 nm = ε [extinction coefficient, also known as molar absorptivity] × C [concentration in M] × l [path length in cm of the cuvette in which the sample is contained]) to calculate the concentration of FAD. The concentration of FAD in the purified sample was then divided by the concentration of the MICAL\textsuperscript{redoxCH} proteins in the purified sample to determine the percentage (stoichiometry) of FAD bound to the purified MICAL proteins.

**NADPH and NADH Consumption.** NADPH and NADH (the reduced form of the coenzymes) absorb light at 340 nm, while the oxidized forms (NADP\textsuperscript{+} and NAD\textsuperscript{+}) do not. This difference between the oxidized and reduced forms of the coenzymes makes it straightforward to measure the conversion of one to another in enzyme assays. Thus, the enzymatic activity of Mical was monitored by the rate of NADPH or NADH oxidation, which is measured by the rate of decreasing light absorbance at 340 nm (extinction coefficient 340 = 6.2 m\textsuperscript{-1} cm\textsuperscript{-1}). 600 nM of the different MICALs to 100 μM NADPH in General Actin Buffer was used. In the absence of F-actin (Fig. 1g,h), NADPH and NADH consumption was monitored and reported as described\textsuperscript{76}. In the presence of F-actin (Figs 3a, 5d), NADPH consumption was monitored and reported as described\textsuperscript{15,16}. In particular, the basal NADPH consumption was measured in the presence of different concentrations of F-actin for the first 3 min before adding the MICALs. The MICAL enzymatic activity was determined by subtracting the NADPH consumption after addition of the MICAL\textsuperscript{redoxCH} from basal NADPH consumption. The rate of NADPH consumption was determined by 10 sec intervals at the maximum rate.

**MICALs and F-actin Co-sedimentation Assays.** Standard approaches in multiple independent experiments (n > 3) were used for high-speed sedimentation/co-sedimentation assays\textsuperscript{11,13,16,17; Cytoskeleton, Inc.}. In brief, purified non-muscle actin (85% β-actin, 15% γ-actin; Cytoskeleton, Inc.) was resuspended to 1 mg/ml in a general actin resuspension buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl\textsubscript{2}). The resuspended actin was then added to a standard actin polymerization buffer (50 mM KCl, 2 mM MgCl\textsubscript{2}, 1 mM ATP) and allowed to polymerize for 1 h at room temperature. This generated an F-actin stock at 23 μM actin. dMical\textsuperscript{redoxCH} protein, hMICAL\textsuperscript{redoxCH}-1, hMICAL\textsuperscript{redoxCH}-2, hMICAL\textsuperscript{redoxCH}-3, hMICAL\textsuperscript{redoxCH}-1 DG protein, or a negative control (bovine serum albumin (BSA), Cytoskeleton, Inc) were subjected to initial (clarification) high-speed centrifugation at 150,000 × g for 1 h at 4 °C. Test proteins (at a final concentration of 2 μM) were then added to separate tubes and incubated with either F-actin (at a final concentration of 18.4 μM) or with F-actin buffer only for 30 min at room temperature. An F-actin only tube was also incubated for 30 min at room temperature. All test tubes were then subjected to high-speed centrifugation at 150,000 × g for 1.5 h at 24 °C. Supernatants were carefully removed and added to sample buffer for loading on an SDS-PAGE gel. The pellet was resuspended in Milli-Q H\textsubscript{2}O with pipetting, incubation on ice for 10 min, and then more pipetting before being added to sample buffer for loading on an SDS-PAGE gel. The gel was then stained with Coomassie blue using standard approaches. The intensity of each of the stained bands in the pellet and soluble fraction was then analyzed and quantified by densitometry using Image J (NIH) and the percentage of different purified proteins with F-actin in the pelleted fraction was presented. Similar approaches and as described previously for Drosophila Mical\textsuperscript{redoxCH} were also used for mutant actins\textsuperscript{15}.  

**Microtubule Co-sedimentation and Polymerization Assays.** Tubulin was obtained from Cytoskeleton, Inc and standard approaches were used for the microtubule co-sedimentation assays\textsuperscript{82,83; Cytoskeleton, Inc} and as we have previously employed for Drosophila Mical\textsuperscript{redoxCH}11. In brief, microtubules were generated by polymerizing tubulin (from a 5 mg/ml tubulin stock containing 1 mM GTP; Cytoskeleton, Inc) at 35 °C for 20 min in a polymerization buffer (80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl\textsubscript{2}, 7.5% glycerol). Microtubules were then diluted 10 fold in a warm buffer (35 °C) containing 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl\textsubscript{2}, and 20 μM taxol. Test proteins including hMICAL\textsuperscript{redoxCH}-1, hMICAL\textsuperscript{redoxCH}-2, hMICAL\textsuperscript{redoxCH}-3, hMICAL\textsuperscript{redoxCH}-1 DG protein (1 μM final concentration), a negative control (bovine serum albumin (BSA) [2.2 μM final concentration, Cytoskeleton, Inc.]), and a positive control (microtubule associated proteins MAPs [0.64 μM final concentration; Cytoskeleton, Inc.]) were added to separate tubes and incubated with either microtubules or buffer for 30 min at room temperature. A microtubule only tube was also incubated for 30 min at room temperature. Each reaction was then subjected to high-speed centrifugation at 100,000 × g for 40 min at 24 °C as described by Cytoskeleton, Inc. Supernatants were then carefully removed and added to sample buffer for loading on an SDS-PAGE gel. The pellet was resuspended in Milli-Q H\textsubscript{2}O with pipetting, incubation on ice for 10 min, and then more pipetting before being added to sample buffer for loading on an SDS-PAGE gel. The gel was then stained with Coomassie blue and visualized with standard approaches. The intensity of each of the stained bands in the pellet and soluble fraction was then analyzed and quantified by densitometry using Image J (NIH) and the percentage of different purified proteins with F-actin in the pelleted fraction was presented. Similar approaches and as described previously for Drosophila Mical\textsuperscript{redoxCH} were also used for mutant actins\textsuperscript{15}. In brief, tubulin (bovine tubulin; Cytoskeleton, Inc.) polymerization was performed in a microtubule polymerization buffer (80 mM PIPES pH 6.9, 2 mM MgCl\textsubscript{2}, 0.5 mM EGTA, 15% glycerol, 1 mM GTP and 5 μM fluorescent reporter (DAPI)) containing mixed tubulin (2 mg/ml final concentration), dMical\textsuperscript{redoxCH} protein, hMICAL\textsuperscript{redoxCH}-1, hMICAL\textsuperscript{redoxCH}-2, hMICAL\textsuperscript{redoxCH}-3, hMICAL\textsuperscript{redoxCH}-1 DG protein (0.6 μM final concentration) and/or NADPH (100 μM). The polymerization was initiated by raising the temperature from 4 °C to 37 °C. Fluorescence intensity was monitored for 1 h at 450 nm with excitation at 360 nm by a fluorescence spectrophotometer (Spectra max M2; Molecular Devices) with temperature control.
Actin Polymerization and Depolymerization Assays. Pyrene-actin polymerization assays were performed using standard approaches\textsuperscript{16} (Cytoskeleton, Inc.) and as we have previously employed for Drosophila MICAL\textsuperscript{redoxCH \textsubscript{1}},\textsuperscript{11,13,16-20}. In brief, purified rabbit skeletal muscle actin (pyrene-labeled; Cytoskeleton, Inc.) was used to monitor actin polymerization since the fluorescence intensity of the pyrene-labeled polymer is substantially higher than the pyrene-labeled monomer. G-actin (monomeric actin) was resuspended to 9.2 μM in a G-actin buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl\textsubscript{2}, 0.2 mM ATP and 1 mM DTT) and incubated on ice for 1 hour. Before all the experiments, G-actin solution was centrifuged for 1 hour at 100,000 g at 4 °C to remove residual actin nucleating centers. Multiple independent experiments (n > 3 by two independent researchers) were performed for each condition such that MICAL proteins, NADPH (MP Biomedicals), and/or NADH (MP Biomedicals) were then added to the actin in a 96 well plate and polymerization was initiated (Time = 0) at 25 °C by the addition of 5 mM Tris-HCl pH 7.5, 50 mM KCl, 2 mM MgCl\textsubscript{2}, 1 mM EGTA, 0.5 mM DTT, and 0.2 mM ATP (to the 96 well plate with 2–5 seconds gentle shaking using the shaking feature of the fluorescence spectrophotometer). Actin was used at a final concentration of 1.1 μM. Fluorescence intensity was immediately monitored at 407 nm with excitation at 365 nm by a fluorescence spectrophotometer (Spectra max M2; Molecular Devices).

To examine the ability of MICALs to induce depolymerization in conditions that favored polymerization (see also\textsuperscript{16}), multiple independent experiments (n > 3 by two independent researchers) were performed similar to described previously for both pyrene-actin and non-pyrene wild-type and Actin M4447L sedimentation assays\textsuperscript{1,11,16-20}. MICAL proteins and/or NADPH were then added to the polymerized actin as described for the polymerization assays (Time = 0) and depolymerization was immediately monitored by fluorescence intensity or via sedimentation as described above. In some cases, as described in the results/figures, MICAL proteins and NADPH were added together before adding them to the F-actin (pre-actin incubation) and in some cases, MICAL proteins were added to F-actin in which NADPH had already been incubated (post-actin incubation). In some cases, as described in the results/figures, additional NADPH was added to the F-actin/MICAL mix at a later time. Note also that these experiments were done using standard approaches and that the F-actin was not stabilized (i.e., by adding a stabilizing protein).

Analysis of MICAL-oxidized actin. Actin was polymerized to generate F-actin and 600 nM of each of the human MICALs and 200–300 μM of NADPH were added to 1.15 μM F-actin at room temperature for 2 hours. The MICAL/NADPH/F-actin reaction was then stopped by adding loading buffer containing β-mercaptoethanol and boiling samples for 5 min. All samples were then loaded into a 12% SDS-PAGE gel, transferred to PVDF membrane, blocked with 5% non-fat milk/TBST buffer for 1 hour and then incubated for 1 hour with a 1:500 dilution of the actin MetO44 antibody\textsuperscript{18}.

SelR-treatment of MICAL-oxidized Actin. Purified pyrene-labeled rabbit skeletal muscle actin (Cytoskeleton, Inc.) was resuspended in G-actin buffer to 2.3 μM. The resuspended actin was then polymerized with 2X polymerization buffer (1.15 μM actin = final concentration) in the presence of human MICAL-1\textsuperscript{redoxCH \textsubscript{2}}, human MICAL-2\textsuperscript{redoxCH \textsubscript{2}}, human MICAL-3\textsuperscript{redoxCH \textsubscript{2}}, or human MICAL-1\textsuperscript{redoxCH \textsubscript{2}} DG and 100 μM NADPH for 1 hour. The NADPH was then removed from the human MICAL-treated actin as described previously\textsuperscript{13,14} (using a centrifugal filter [Amicon Ultra, Ultracel-10K, Millipore]). The human MICAL-treated actin was then either treated with SelR or the buffer the SelR was stored in (containing the 10 mM MgCl\textsubscript{2} and 20 mM DTT) for 1 hour at 37 °C.

Hydrogen Peroxide Production. In one method, we used the substrate luminol and the generation of a chemiluminescence signal that we visualized on either X-ray film or a phosphoimager. In particular, luminol, when it becomes oxidized by peroxide (peroxide can be formed through a reaction of H\textsubscript{2}O\textsubscript{2} with horseradish peroxidase [HRP]), results in creation of an excited state product, which then decays to a lower energy state by releasing photons of light\textsuperscript{87}. Therefore, to perform this reaction and to test for the ability of the different MICALs to form H\textsubscript{2}O\textsubscript{2}, we added a substrate (luminal [i.e., ECL substrate]), a catalyst (HRP), and the MICALs in the presence of NADPH (which will provide H\textsubscript{2}O\textsubscript{2} if they generate it). To do this, we incubated 0.6 μM of each MICAL in the presence of 200 μM NADPH, HRP (the catalyst), and luminol, and then visualized the product of the reaction using either X-ray film or a phosphoimager.

As another (different) means to detect H\textsubscript{2}O\textsubscript{2}, we used the ROS-Glo H\textsubscript{2}O\textsubscript{2} Assay Kit developed by Promega (Catalog No: G8820),\textsuperscript{98} and followed the manufacturers recommended instructions. In particular, in the ROS-Glo H\textsubscript{2}O\textsubscript{2} Assay Kit, a derivatized luciferin substrate is incubated with a potential H\textsubscript{2}O\textsubscript{2} generating sample, and then the derivatized luciferin substrate reacts directly with H\textsubscript{2}O\textsubscript{2} to generate a luciferin precursor. Addition of the ROS-Glo detection solution converts the precursor to luciferin and triggers the luciferase to produce a light signal that is proportional to the amount of H\textsubscript{2}O\textsubscript{2} present in the sample. Thus, the ROS-Glo H\textsubscript{2}O\textsubscript{2} substrate reacts directly with H\textsubscript{2}O\textsubscript{2}, eliminating the need for HRP as a coupling enzyme (and thus eliminating any false detection of H\textsubscript{2}O\textsubscript{2} associated with any unknown activation or inhibition of HRP by the MICALs). In particular, 60 pmol of each of the Drosophila and human MICAL\textsuperscript{redoxCH \textsubscript{2}} proteins was diluted by General Actin Buffer to a final volume of 79 μl and transferred into a 96-well plate (Corning). 25 μM of H\textsubscript{2}O\textsubscript{2} was used as the standard. Following the manufacturer’s recommended protocol, the H\textsubscript{2}O\textsubscript{2} substrate dilution buffer (SDB) was thawed and placed on ice. The SDB was then mixed with the manufacturer-provided H\textsubscript{2}O\textsubscript{2} substrate (the derivatized luciferin substrate) just prior to use (generating the SDB-S). 20 μl of SDB-S was added into each well containing the MICALs or the H\textsubscript{2}O\textsubscript{2} standard to generate a final volume of 100 μl. A control SDB-S only well was also used. At time 0 min (reaction time: 10 min), 5 min (reaction time: 5 min), 8 min (reaction time: 2 min), 1 μl of 10 mM NADPH (final concentration: 100 μM) was added into each well. 100 μl of ROS-Glo detection solution (+1 μl D-Cys and 1 μl enhancer solution/100 μl Detection solution) was added to each well. After the 96-well plate was incubated for 5 min at room temperature, the relative luminescence unit was recorded by using a plate-reading luminometer (TriStar\textsuperscript{7} LB 942 Multidetection Microplate Reader, Berthold Technologies, Germany). H\textsubscript{2}O\textsubscript{2} concentration was calculated by the luminescence value of the samples, zero control and the standard sample (25 μM H\textsubscript{2}O\textsubscript{2}).
It should also be noted that the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) has been used in the past to determine the amount of H$_2$O$_2$ generated by MICAL-1$^{190}$. We and others have determined that this Amplex Red reagent is artifactually fast and an inaccurate measure of MICAL-mediated H$_2$O$_2$ production$^{89,90}$. It should be noted, however, that we did see similar relative amounts of “H$_2$O$_2$” generated with this reagent (i.e., MICAL-1 generated the most reaction product and MICAL-2 generated the least) when we used this reagent to compare each of the MICALs (data not shown).

**Oxygen Consumption.** The electrode was prepared by adding 50% saturated KCl solution as electrolyte in the electrode well. The well was then covered with a paper spacer to provide a continuous electrolyte layer on the electrode and with an oxygen-permeable membrane on top of the paper separator to separate the electrolyte from the sample. Then a glass reaction vessel was placed on top of the electrode chamber and closed with a gas-tight plunger to provide an almost sealed space for the sample with a small opening on top to inject reagents. Lastly, the electrode was calibrated using dissolved oxygen in water (which provided a basal line as a sample) and then establishing a zero content of oxygen by adding an oxygen reducing agent to the water. The basal oxygen consumption was then determined by adding 200 µM of NADPH and 600 nM of each MICAL into F-actin buffer (no F-actin) (1:1 G-Buffer + 2X Polymerization Buffer) in the chamber and measuring the change in the amount of oxygen dissolved in the buffer via the oxygen electrode.

**Drosophila Transgenic Fly Lines.** To generate hMICAL-1$_{\text{redoxCH}}$ pUAST, the following primers were used: EcoRI-For: 5′-AGCT GAATTC ATG GCT TCA CCT ACC TCC AC-3′ and NotI-Rev: 5′- AGCT GCGGCCGC TTA GTG GTG GTG GTG GTG CTC GAG TCT AGA CTT AAA CAT CTC GTA GAA CTG A-3′. Both PCR product and the pUAST vector were digested with EcoRI and NotI and the purified DNA fragments were ligated and sequenced on both strands. To generate hMICAL-2$_{\text{redoxCH}}$ pUAST, the following primers were used: NotI-For: 5′-AGCT GCCGCCGC ATG GAG GAG AGG AAG CAT GA-3′ and NheI-Rev: 5′-AGCT GCTAGCT TTA GTG GTG GTG GTG GTG GTG GTG GTG CTC GAG TCT AGA CCG GAA GAG CTC GTA GAA CT-3′. Both PCR product and the pUAST vector were digested with NotI and NheI (pUAST digested with XbaI) and the purified DNA fragments were ligated. To generate hMICAL-3$_{\text{redoxCH}}$ pUAST, the following primers were used: NotI-pUAST-For: 5′-AGCT GCCGCCGC ATG GAG GAG AGG AAG CAT GA-3′ and KpnI-Rev: 5′-AGCT GCTAGCT TTA GTG GTG GTG GTG GTG GTG GTG CTC GAG TCT AGA CCG GAA GAG CTC GTA GAA CT-3′. Both PCR product and the pUAST vector were digested with NotI and KpnI and the purified DNA fragments were ligated.

**In Vivo F-actin and Cellular Assays.** Multiple different transgenic fly lines for each of the MICALs were generated (n > 5) and transgenic fly lines of the same genotypes showed similar defects when expressed with the bristle-specific B11-GAL4 driver. Analysis of the effects on F-actin and cellular remodeling was done in vivo using the Drosophila bristle process as previously described$^{11,14,16,17}$. To visualize F-actin, Drosophila pupae were placed on double-sided tape and the dorsal surface of the pupal case was removed, allowing the pupae to be lifted from their case and immediately placed in depression-well slides and imaged. One copy of UAS$_{\text{GFP}}$GFP$_{\text{actin}}$ was used to visualize F-actin and imaging was done using a Zeiss LSM510 confocal microscope. Examination of bristle cell remodeling was performed on young, recently emerged adult offspring. The images and drawings of the adult bristles were done with the aid of a Zeiss Discovery M$^2$ Bio stereomicroscope, a motorized focus and zoom, and three-dimensional reconstruction software (Extended Focus Software; a kind gift from Bernard Lee).

**Statistics and Reproducibility.** For each representative protein purification, image, gel, immunoblot, graph, or in vivo experiment, the experiments were repeated at least two separate independent times and there were no limitations in repeatability. At least two independent protein purifications and multiple independent actin biochemical experiments were performed with similar results including reproducing the effects independently from different researchers. No statistical method was used to predetermine the sample size, which was based on what is published in the field. Differences between experimental and control animal conditions were large, with little variability and so the sample size was larger than needed to ensure adequate power to detect an effect. Animal studies were based on pre-established criteria to compare against age-matched animals. Animal experiments were not randomized. Animals of the correct genotype were determined and those collected of that genotype were included as data. For genetic experiments, in which the genotype needed to be determined on the basis of different Drosophila genetic/chromosome markers, blinding was not employed. The figure legends list the sample size for each experiment. To the best of our knowledge the statistical tests are justified as appropriate.

**Data availability.** All data generated or analysed during this study are included in this published article (and its Supplementary Information files). All materials, data and associated protocols will be made promptly available to others without preconditions.

**References**

1. Pollard, T. D. & Cooper, J. A. Actin, a central player in cell shape and movement. *Science* **326**, 1208–1212 (2009).
2. Fletcher, D. A. & Müllerins, R. D. Cell mechanics and the cytoskeleton. *Nature* **463**, 485–492 (2010).
3. Carlier, M. F., Ferguson, J., Montaville, P., Shekhar, S. & Kuhn, S. Control of polarized assembly of actin filaments in cell motility. *Cell Mol Life Sci* **72**, 3051–3067 (2015).
4. Siripala, A. D. & Welch, M. D. SnapShot: actin regulators I. *Cell* **128**, 626 (2007).
5. Siripala, A. D. & Welch, M. D. SnapShot: actin regulators II. *Cell* **128**, 1014 (2007).
6. Blanchin, L., Boujemaa-Paterski, R., Sykes, C. & Plastino, J. Actin dynamics, architecture, and mechanics in cell motility. *Physiol Rev* **94**, 235–263 (2014).
7. Pollard, T. D. & Borisy, G. G. Cellular motility driven by assembly and disassembly of actin filaments. *Cell* **112**, 453–465 (2003).
35. Kirilly, D.
33. Beuchle, D., Schwarz, H., Langegger, M., Koch, I. & Aberle, H. Drosophila MICAL regulates myofilament organization and synaptic
31. Van Battum, E. Y.
32. Lundquist, M. R.
49. Chambers, J. C.
47. Wang, Y.
48. Marotta, M.
44. Mariotti, S.
42. Ho, J. R.
41. Ashida, S.
40. Zhou, Y.
38. Grigoriev, I.
27. Morinaka, A.
24. Giridharan, S. S. & Caplan, S. MICAL-Family Proteins: Complex Regulators of the Actin Cytoskeleton.
23. Vanoni, M. A., Vitali, T. & Zucchini, D. MICAL, the Flavoenzyme Participating in Cytoskeleton Dynamics.
22. Zhou, Y., Gunput, R. A., Adolfs, Y. & Pasterkamp, R. J. MICALs in control of the cytoskeleton, exocytosis, and cell death.
19. Schmidt, E. F., Shim, S. O. & Strittmatter, S. M. Release of MICAL autoinhibition by semaphorin-plexin signaling promotes
interaction with collapsin response mediator protein. J Neurosci 28, 2287–2297 (2008).
18. Wilson, C., Terman, J. R., Gonzalez-Billault, C. & Ahmed, G. Actin filaments - a target for redox regulation. Cytoskeleton (Hoboken) 73, 577–595 (2016).
17. Yoon, J., Kim, S. B., Ahmed, G., Shay, J. W. & Terman, J. R. Amplification of F-Actin Disassembly and Cellular Repulsion by Growth
Factor Signaling. Dev Cell 42, 117–129 (2017).
16. Grintsevich, E. E.
15. Lee, B. C.
14. Brieher, W. Mechanisms of actin disassembly.
11. Hung, R. J.
10. Brieher, W. Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics. Int Rev Cytol 258, 1–82 (2007).
9. Bugyi, B. & Carlier, M. F. Control of actin filament treadmilling in cell motility. Annu Rev Biophys 39, 449–470 (2010).
8. Ono, S. Mechanisms of redox regulation of F-actin disassembly. J Cell Sci 125, 614–624 (2012).
7. Hou, S. T. et al. Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage. Sci Rep 5, 7890 (2015).
6. Liu, Q. et al. MICAL3 flavoprotein monooxygenase forms a complex with centralspindlin and regulates cytokinesis. J Biol Chem 291, 20617–20629 (2016).
5. Fremont, S. et al. Oxidation of F-actin controls the terminal steps of cytokinesis. Nat Commun 8, 14528 (2017).
4. Grigoriev, I. et al. Rab6, Rab8, and MICAL3 Cooperate in Controlling Docking and Fusion of Exocytotic Carriers. Curr Biol 21, 967–974 (2011).
3. Bachmann-Gagescu, R. et al. The Ciliopathy Protein CC2D2A Associates with NINL and Functions in Rab8-MICAL3-Regulated Vesicle Trafficking. PLoS Genet 11, e1005575 (2015).
2. Zhou, Y. et al. MICAL-1 is a Negative Regulator of MST-NDR Kinase Signaling and Apoptosis. Mol Cell Biol 31, 3603–3615 (2011).
1. Ashida, S. et al. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res 12, 2767–2773 (2006).
54. Tochigi, M. et al. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. *Neurosci Lett* **60**, 184–191 (2008).
55. Crews, D. et al. Epigenetic transgenerational inheritance of altered stress responses. *Proc Natl Acad Sci USA* **109**, 9143–9148 (2012).
56. Mychasiuk, R., Gibb, R. & Kolb, B. Prenatal stress produces sexually dimorphic and regionally specific changes in gene expression in hippocampus and frontal cortex of developing rat offspring. *Dev Neurosci* **33**, 531–538 (2011).
57. Parikh, N. N. et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. *Cell* **155**, 1008–1021 (2013).
58. Muller, T. et al. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). *Mol Biol Cell* **18**, 201–210 (2007).
59. Aenlle, K. K., Kumar, A., Cui, L., Jackson, T. C. & Foster, T. C. Estrogen effects on cognition and hippocampal transcription in middle-aged mice. *Neurobiol Aging* **30**, 932–945 (2009).
60. Bredrup, C. et al. Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the ITF-A gene WDR19. *Am J Hum Genet* **89**, 634–641 (2011).
61. Li, W. D. et al. A genome wide association study of plasma uric acid levels in obese cases and never-overweight controls. *Obesity (Silver Spring)* **21**, E490–494 (2013).
62. Vitali, T., Maffioli, E., Tedeschi, G. & Vanoni, M. A. Properties and catalytic activities of MICAL1, the flavoenzyme involved in cytoskeleton dynamics, and modulation by its CH, LIM and C-terminal domains. *Arch Biochem Biophys* **593**, 24–37 (2016).
63. Alqassim, S. S. et al. Modulation of MICAL Monooxygenase Activity by its Calponin Homology Domain: Structural and Mechanistic Insights. *Sci Rep* **6**, 22176 (2016).
64. Nadella, M., Bianchet, M. A., Gabelli, S. B., Barrila, J. & Anzeli, L. M. Structure and activity of the axon guidance protein MICAL. *Proc Natl Acad Sci USA* **102**, 16830–16835 (2005).
65. Siebold, C. et al. High-resolution structure of the catalytic region of MICAL protein (molecule interacting with CasL), a multidomain flavoenzyme-signaling molecule. *Proc Natl Acad Sci USA* **102**, 16836–16841 (2005).
66. van Berkel, W. J. H. & Muller, F. In *Chemistry and biochemistry of flavoenzymes Vol. 2* (ed F. Muller) 1–29 (CRC Press, 1991).
67. Hung, R.-J. & Terman, J. R. Extracellular inhibitors, repellents, and Semaphorin/Plexin/MICAL-mediated actin filament disassembly. *Cytoskeleton* **68**, 415–433 (2011).
68. Vanoni, M. A. Structure-function studies of MICAL, the unusual multidomain flavoenzyme involved in actin cytoskeleton dynamics. *Arch Biochem Biophys* **632**, 118–141 (2017).
69. Eppink, M. H., Schreuder, H. A. & Van Berkel, W. J. Identification of a novel conserved sequence motif in flavoprotein hydroxylases with a putative dual function in FAD/NAD(P)H binding. *Protein Sci* **6**, 2454–2458 (1997).
70. Sutherland, J. D. & Witke, W. Molecular genetic approaches to understanding the actin cytoskeleton. *Curr Opin Cell Biol* **11**, 142–151 (1999).
71. Tilney, L. G. & DeRosier, D. J. How to make a curved Drosophila bristle using straight actin bundles. *Proc Natl Acad Sci USA* **102**, 18785–18792 (2005).
72. Rottner, K. & Stradal, T. E. Actin dynamics and turnover in cell motility. *Curr Opin Cell Biol* **23**, 569–578 (2011).
73. Miyoshi, T. & Watanabe, N. Can filament treadmilling alone account for the F-actin turnover in lamellipodia? *Cytoskeleton (Hoboken)* **70**, 179–190 (2013).
74. Kim, G., Weiss, S. I. & Levine, R. L. Methionine oxidation and reduction in proteins. *Biochim Biophys Acta* **1840**, 901–905 (2014).
75. Bashaw, G. J. & Klein, R. Signaling from axon guidance receptors. *Cold Spring Harb Perspect Biol* **2**, a019419 (2010).
76. Wu, H., Hung, R. J. & Terman, J. R. A simple and efficient method for generating high-quality recombinant Mical enzyme for *in vitro* assays. *Protein Expr Purif* **127**, 116–124 (2016).
77. Gupta, N., Wu, H. & Terman, J. R. Data presenting a modified bacterial expression vector for expressing and purifying Nus solubility-tagged proteins. *Data Brief* **6**, 1227–1231 (2016).
78. Aliverti, A., Curti, B. & Vanoni, M. A. Identifying and quantitating FAD and FMN in simple and in iron-sulfur-containing flavoproteins. *Methods Mol Biol* **131**, 9–23 (1999).
79. Macheroxou, P. UV-visible spectroscopy as a tool to study flavoproteins. *Methods Mol Biol* **131**, 1–7 (1999).
80. Lenerink, N. G., van den Berg, W. A. & van Berkel, W. J. l-Galactono-gamma-lactone dehydrogenase from Arabidopsis thaliana, a flavoprotein involved in vitamin C biosynthesis. *FEBS J* **275**, 713–726 (2008).
81. Yin, H. L. & Stossel, T. P. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. *Nature* **281**, 583–586 (1979).
82. Al-Bassam, J., Roger, B., Halpain, S. & Milligan, R. A. Analysis of the weak interactions of ADP-Unc104 and ADP-kinesin with microtubules and their inhibition by MAP2c. *Cell Motil Cytoskeleton* **34**, 377–389 (1997).
83. Gustke, N., Trinczek, B., Biemar, J., Mandelkow, E. M. & Mandelkow, E. Domains of tau protein and interactions with microtubules. *Biochemistry* **33**, 9511–9522 (1994).
84. Bonne, D., Heusele, C., Simon, C. & Pantaloni, D. 4′,6-Diamidino–2-phenylindole, a fluorescent probe for tubulin and microtubules. *J Biol Chem* **260**, 2819–2825 (1985).
85. Cooper, J. A. In *The Cytoskeleton: A Practical Approach The Practical Approach Series* (eds K.L. Carraway & C.A.C. Carraway) 47–71 (Oxford University Press, 1992).
86. Yoon, J., Hung, R. J. & Terman, J. R. Characterizing F-actin disassembly induced by the semaphorin-signaling component MICAL. *Methods in Molecular Biology* **1493**, 119–128 (2017).
87. Heindl, D. & Josel, H. P. In *Nonradioactive analysis of biomolecules* *Springer Lab Manuals* (ed C. Kessler) (Springer, 2000).
88. Duwel, M., S. Shultz, J., Vaidyasar, G. & Cali, J. A new luminescent assay for detection of reactive oxygen species. Available from: http://www.promega.com/resources/publish/a-luminescent-assay-for-detection-of-reactive-oxygen-species/ (2013).
89. Zucchini, D., Caprini, G., Pasterkamp, R. J., Tedeschi, G. & Vanoni, M. A. Kinetic and spectroscopic characterization of the putative monoxygenase domain of human MICAL-1. *Arch Biochem Biophys* **515**, 1–13 (2011).
90. McDonald, C. A., Liu, Y. Y. & Palley, B. A. Actin stimulates reduction of the MICAL-2 monooxygenase domain. *Biochemistry* **52**, 6076–6084 (2013).
91. Wiernenga, R. K., Terpstra, P. & Hol, W. G. Prediction of the occurrence of the ADP-binding beta alpha beta-fold in proteins, using an amino acid sequence fingerprint. *J Mol Biol* **187**, 101–107 (1986).
92. Eggink, G., Engel, H., Vriend, G., Terpstra, P. & Witholt, B. Rubredoxin reductase of Pseudomonas oleovorans. Structural relationship to other flavoprotein oxidoreductases based on one NAD and two FAD fingerprints. *J Mol Biol* **212**, 135–142 (1990).
93. Chapman, S. K. & Reid, G. A. In *Methods in Molecular Biology* Vol. 131, 256 (Humana Press, Totowa, NJ, 1999).

**Acknowledgements**

We thank G. Ahmed and members of the Terman lab for comments and R.J. Hung for reagents and technical assistance. We also thank J. Sudderth and R. Deberardinis for assistance with oxygen consumption assays. Supported by NIH (NS073968; MH085923) and Welch Foundation (I-1749) grants to J.R.T.
Author Contributions
H.W., H.G.Y., J.Y. and J.R.T. designed/performed experiments and analyzed data. H.W. and J.R.T. prepared the manuscript and wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-17943-5.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018